Phase II Study Evaluating the Effect of Concomitant Ramucirumab on the Pharmacokinetics of Docetaxel in Patients with Advanced Solid Tumors

Mark N Stein*, Laura Q M Chow, David C Smith, Dale R Shepard, Ding Wang, John Powderly, Archana Chaudhary, Yong Lin and Ling Gao

1 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
2 University of Washington, Seattle, WA, USA
3 University of Michigan, Ann Arbor, MI, USA
4 Cleveland Clinic Foundation, Cleveland, OH, USA
5 Henry Ford Hospital, Detroit, MI, USA
6 Carolina Biooncology Institute, Huntersville, NC, USA
7 Eli Lilly and Company, Indianapolis, IN, USA
8 Eli Lilly and Company, Bridgewater, NJ, USA

Abstract

Background: Ramucirumab is a human IgG1 monoclonal antibody that specifically targets the vascular endothelial growth factor receptor-2. The primary objective of this study was to investigate the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel.

Methods: Patients with metastatic or locally advanced malignant solid tumors resistant to standard therapy or for which no standard therapy was available were recruited. Patients received docetaxel 75 mg/m² and ramucirumab 10 mg/kg on day 1 of a 3-week cycle. In cycle 1, docetaxel was administered alone; in cycle 2 and subsequent cycles, ramucirumab was administered followed by docetaxel. Blood was drawn immediately before and at regular intervals after infusions for cycles 1 and 2 to determine docetaxel and ramucirumab concentrations.

Results: Docetaxel pharmacokinetic parameters were assessed in 18 patients. The dose-normalized area under the plasma concentration versus time curve from time zero extrapolated to infinity and maximum plasma drug concentration after infusions for cycles 1 and 2 were similar to those when docetaxel was administered alone during cycle 1, with geometric least squares means ratios of 0.97 (90% CI: 0.84, 1.10) for the area under the plasma concentration versus time curve from time zero extrapolated to infinity and 1.14 (90% CI: 0.84, 1.55) for the maximum plasma drug concentration. Of the 22 patients who received any dose of study drug, the most commonly reported treatment-emergent adverse events included nausea (12 patients, 54.5%), fatigue, leukopenia, and neutropenia (each in nine patients, 40.9%). The most commonly reported grade ≥ 3 treatment-emergent adverse events were leukopenia and neutropenia (each in seven patients, 31.8%).

Conclusions: Co-administration of ramucirumab had no effect on the pharmacokinetics of docetaxel. The incidence and severity of treatment-emergent adverse events were consistent with the known safety profiles of docetaxel and ramucirumab.

Keywords: Ramucirumab; Docetaxel; Drug-drug interactions; Pharmacokinetics

Abbreviations: AUC(0-∞): Area under plasma concentration-time curve; Area under the plasma/serum concentration versus time curve from time zero extrapolated to infinity; AUC(tlast-∞): Plasma/serum concentration versus time curve from time zero until the time of last measurable concentration to infinity; CI: Confidence Interval; CL: Clearance; Cmax: Maximum Plasma/Serum Drug Concentration; DD1: Drug-Drug Interaction; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IgG1: Immunoglobulin G Subclass 1; IQC: Lower Quality Control; LS mean: Least Squares Mean; mAbs: Monoclonal Antibodies; NSCLC: Non-Small Cell Lung Cancer; SAE: Serious Adverse Event; t1/2: Terminal Half-Life; TEAE: Treatment-Emergent Adverse Event; VEGF: Vascular Endothelial Growth Factor; VEGFR-2: VEGF Receptor-2; Vss: Volume of Distribution at Steady State

Introduction

Angiogenesis is required for invasive tumor growth and metastasis, and as such, is a key target for control of cancer progression [1]. Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) are important mediators in tumor-associated angiogenesis [2]. Blockade of VEGF-and VEGFR-2-mediated signaling inhibits the formation of new blood vessels and tumor growth [3].

Ramucirumab is a human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that selectively binds with high affinity to VEGF-2, blocking binding of all VEGF ligands and receptor activation [4]. The results from REVEL, a randomized phase 3 trial in patients with previously treated non-small cell lung cancer (NSCLC) showed that treatment with ramucirumab plus docetaxel significantly improved survival compared to treatment with docetaxel alone (median
over all survival of 10.5 months for patients treated with ramucirumab plus docetaxel versus 9.1 months for patients treated with placebo plus docetaxel [hazard ratio 0.86, 95% confidence interval (CI) 0.75–0.98; \( P = 0.023 \)] [5]. The results of this trial led to U.S. Food and Drug Administration approval for ramucirumab as second-line therapy in patients with advanced NSCLC.

Docetaxel belongs to the class of taxane antineoplastic agents that act by prevention of microtubule depolymerization leading to cell cycle arrest, apoptosis, and cytotoxicity, and it is metabolized in the liver by cytochrome P450 3A isozymes [6]. Docetaxel has activity against various types of malignancies, including breast, lung, ovarian, prostate, and head and neck cancer. It is used as a single agent as second-line therapy in patients with advanced NSCLC and in combination with cisplatin in chemotherapy-naïve patients with metastatic NSCLC [6].

The primary objective of this study was to assess the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in patients with advanced malignant solid tumors resistant to standard therapy or for which no standard therapy was available.

Materials and Methods

Study design

This was a multicenter, open-label, single-arm, cross-comparison study investigating the potential of concomitant ramucirumab to affect the pharmacokinetics of docetaxel. This study was conducted in accordance with the Good Clinical Practices, the Declaration of Helsinki, and approval by the medical institutions’ Ethical Review Board. Patients provided written informed consent prior to inclusion. This trial was registered with ClinicalTrials.gov (NCT01567163).

Eligible patients were ≥ 18 years of age, had metastatic or locally advanced malignant solid tumors that were resistant to standard therapy or for which no standard therapy was available, had adequate organ and hematologic function, had no history of uncontrolled hypertension or bleeding, and had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2. Patients were required to have had 0–1 prior taxane-containing treatment regimens (including taxane monotherapy), which must have been completed at least 6 months before the first dose of study drug. Prior treatment with bevacizumab was allowed.

In cycle 1, docetaxel 75 mg/m² only was administered on day 1 of a 3-week cycle. Combination treatment with ramucirumab 10 mg/kg and docetaxel 75 mg/m² every 3 weeks began on day 1 of cycle 2 and continued through subsequent cycles until treatment ended (Figure 1). Patients could continue treatment until disease progression, the development of intolerable toxicity, or other reasons for study withdrawal. The study design and data analysis followed US FDA guidance [7].

Pharmacokinetic sampling and assay

**Docetaxel:** Blood samples for docetaxel analysis were drawn immediately before (0 h) and after (1 h) the docetaxel infusion, and at 1.5, 2, 3, 5, 7, 24, 48, and 72 h after the start of the docetaxel infusion in cycle 1 (monotherapy) and cycle 2 (coadministered with ramucirumab). Docetaxel concentration in plasma was determined using a validated liquid chromatography with tandem mass spectrometric detection method (Covance Laboratories Inc., Madison, Wisconsin, USA). The lower limit of quantification was 0.00 ng/mL. The inter-assay accuracy (deviation of mean from theoretical%) during validation ranged from -4.7–6.7%. The inter-assay precision (%relative standard deviation) during validation ranged from 4.4–7.6%. Testing to assess the potential

**Ramucirumab:** Blood samples for ramucirumab analysis were drawn immediately before the ramucirumab infusion (-1 h) and after the ramucirumab infusion/pre-docetaxel infusion (0 h) and 1.5, 2, 3, 5, 7, 24, 48, 72, 168, 264, and 336 h after the start of the ramucirumab infusion in cycle 2 (coadministered with docetaxel). Ramucirumab concentration in serum was determined using a validated enzyme-linked immunosorbent assay method (Intertek Pharmaceutical Services, San Diego, California, USA). The lower limit of quantification was 2500.00 ng/mL. The inter-assay accuracy (% relative error) during validation ranged from -24.9–3.9%. The inter-assay precision (% relative standard deviation) during validation ranged from 4.9–17.4%. Interference with docetaxel was also assessed and was determined to have no impact on the quantitation of ramucirumab.

**Pharmacokinetic analysis**

Pharmacokinetic (PK) parameters for ramucirumab and docetaxel were computed by standard noncompartmental methods of analysis using Phoenix’ WinNonlin® Professional 6.2 (Pharsight Corporation, St. Louis, MO, USA).

PK parameters determined for ramucirumab and docetaxel were maximum plasma/serum drug concentration (\( C_{\text{max}} \)), the area under the plasma/serum concentration versus time curve from time zero extrapolated to infinity [\( AUC_{(0-\infty)} \)], clearance (CL), volume of distribution at steady state (\( V_s \)), and terminal half-life (\( t_{1/2} \)). \( AUC_{(0-\infty)} \) and \( C_{\text{max}} \) were dose normalized for the drug-drug interaction (DDI) comparison because patients received different absolute doses.

**Statistical analysis**

A mixed-effect model was used to analyze the log-transformed PK parameters of \( AUC_{(0-\infty)} \) and \( C_{\text{max}} \) for docetaxel with or without
coadministration with ramucirumab. The model contained cycle (docetaxel, ramucirumab + docetaxel) as fixed effect and patient as a random effect. From the model, least squares mean (LS mean) and 90% CI for the differences of $\text{AUC}_{0-\infty}$ and $\text{C}_{\text{max}}$ of docetaxel in log scale between cycle 1 and cycle 2 were estimated; then transformed back to the original scale to estimate the ratio of geometric LS means and 90% CIs for the comparison (ramucirumab+docetaxel vs. docetaxel). Between-patient and within-patient coefficients of variability were also calculated. All calculations were performed using SAS® version 9.2.

Safety

All patients exposed to any dose level of the study treatments during the trial were considered for the analysis of safety.

Results

Patient demographics and disease characteristics

A total of 22 patients received at least one dose of ramucirumab or docetaxel. A summary of patient baseline characteristics is shown in Table 1. Of these 22 treated patients, there were 13 male (59.1%) and nine female (40.9%). The median age of participants was 61.5 years (range 26-74 years). The majority of patients were white (17 patients, 77.3%) and had an ECOG PS of 0 or 1 (21 patients, 95.5%). The median duration of disease was 25.5 months (range 10 to 80 months). The most commonly reported site of origin for the primary tumor was non-small cell lung cancer (five patients, 22.7%), prostate carcinoma and urothelial carcinoma (each in three patients, 13.6%), breast carcinoma and soft tissue sarcoma (each in two patients, 9.1%), and other cancers comprised 7 (31.8%) patients. There were no patients with previous anticancer treatments within 21 days or prior radiotherapy within 14 days of the start of the study.

Pharmacokinetics

Docetaxel: Mean plasma concentration-time profiles of docetaxel as monotherapy and in combination with ramucirumab are presented in Figure 2. The two curves were superimposable. Maximum docetaxel plasma concentrations were achieved at the end of infusion. Table 2 summarizes docetaxel mean PK parameters obtained following docetaxel administration as monotherapy or as combination therapy following ramucirumab administration. Exposure parameters are similar between cycle 1 and cycle 2, showing that docetaxel exposure was not affected by the presence of ramucirumab.

Of the total 22 patients who received at least one dose of docetaxel, four patients did not complete day 1, cycle 2. These four patients were not included in the DDI analysis. Of the 18 patients included in the analysis, docetaxel $\text{AUC}_{0-\infty}$ or $\text{C}_{\text{max}}$ could not be calculated in one patient because of incorrect infusion time in cycle 1. In cycle 2, docetaxel $\text{AUC}_{0-\infty}$ or $\text{C}_{\text{max}}$ could not be calculated in one patient because of nonavailability of docetaxel concentrations due to a nonfrozen sample (N=17), and $\text{AUC}_{0-\infty}$ for one additional patient was not included in summary statistics or included in statistical analysis of PK parameters because the area under the plasma/serum concentration versus time curve from time zero until the time of last measurable concentration to infinity ($\text{AUC}_{0\to\infty}$) was >30% (N=16).

The effect of coadministration of ramucirumab on the pharmacokinetics of docetaxel assessed by statistical analysis is shown in Table 3. Dose-normalized $\text{AUC}_{0-\infty}$ and $\text{C}_{\text{max}}$ of docetaxel as combination therapy in cycle 2 were similar to those when docetaxel was administered alone in cycle 1, with ratios of geometric LS means (90% CI) at 0.97 (90% CI: 0.84, 1.10) for $\text{AUC}_{0-\infty}$ and 1.14 (90% CI: 0.84, 1.55) for $\text{C}_{\text{max}}$. Although the $\text{C}_{\text{max}}$ of docetaxel showed a 14% increase when administered in combination with ramucirumab, there was no consistent pattern of increase observed for each patient (Figure 3), indicating a lack of consistency in the increase observed for the mean $\text{C}_{\text{max}}$.

Table 1: Patient characteristics.

| Parameter                           | Geometric Mean (CV%)                  |
|-------------------------------------|---------------------------------------|
|                                     | Docetaxel Alone (cycle 1) n=21        | Docetaxel + Ramucirumab (cycle 2) n=17 |
| $\text{C}_{\text{max}}$             | 1210.51 (1294.77)                     |                                         |
| (ng/mL)                             | -88                                   | -35                                    |
| Dose-normalised $\text{C}_{\text{max}}$ | 8.18                                   | 8.78                                   |
| (ng/mL/mg)                          | -90                                   | -37                                    |
| $t_{1/2}$                           | 25.2 (30.2)                           |                                         |
| (h)                                 | (7.62-66.9) (16.5-61.8)               |                                         |
| $\text{AUC}_{0-\infty}$            | 1970 (1920)                           |                                         |
| (ng x h/mL)                         | -47                                   | -32                                    |
| Dose-normalised $\text{AUC}_{0-\infty}$ | 13.3 (12.8)                           |                                         |
| (ng x h/mL/mg)                      | -54                                   | -30                                    |
| CL                                  | 75.0 (78.1)                           |                                         |
| (L/h)                               | -54                                   | -30                                    |
| $V_{s}$                             | 1280 (1660)                           |                                         |
| (L)                                 | -111                                  | -44                                    |

Table 2: Mean pharmacokinetic parameters of docetaxel administered as monotherapy or as combination therapy with ramucirumab.
The 90% CI of $C_{\text{max}}$ includes 1.00, and the 90% CI for $AUC_{(0-\infty)}$ is within the interval of 0.80-1.25, indicating that coadministration of docetaxel with ramucirumab had no effect on the pharmacokinetics of docetaxel.

**Ramucirumab:** Summary statistics for mean PK parameters of ramucirumab when coadministered with docetaxel are shown in Table 4. The exposure parameters for ramucirumab plus docetaxel were similar to those found for ramucirumab monotherapy [8]. The geometric mean dose-normalized $C_{\text{max}}$ of ramucirumab plus docetaxel was similar to ramucirumab alone (0.365 µg/mL/mg vs. 0.358 µg/mL/mg, respectively). The geometric mean dose-normalized $AUC_{(0-\infty)}$ for ramucirumab plus docetaxel was 54.4 µg × h/mL/mg compared to 55.3 µg × h/mL/mg for ramucirumab monotherapy.

Figure 4 compares the distribution of dose-normalized ramucirumab exposure parameters, $C_{\text{max}}$ and area under plasma concentration-time curve (AUC) with and without concomitant docetaxel. The results show the distribution of dose-normalized ramucirumab exposure parameters, $C_{\text{max}}$ and AUC, in two groups of patients where one group was administered ramucirumab alone [8] and the other group was administered ramucirumab in combination with docetaxel. Median values are similar between ramucirumab monotherapy and ramucirumab administered with docetaxel for each parameter, showing that coadministration of ramucirumab and docetaxel is unlikely to impact the pharmacokinetics of ramucirumab.

**Safety**

Of the 22 patients in the safety population, 21 patients experienced a treatment-emergent adverse event (TEAE) regardless of relationship, 14 of whom experienced a grade ≥ 3 TEAE. The most commonly reported grade ≥ 3 TEAEs were leukopenia and neutropenia (each in seven patients, 31.8%) (Table 5). No TEAEs led to discontinuations of either study drug, and no deaths occurred during the study by the cutoff date of December 31, 2012. Four patients had dose modifications or dose interruptions due to TEAEs. These TEAEs were grade 1 chest discomfort; grade 2 fatigue, anorexia, and infusion-related reaction; and grade 4 neutropenia.

The most commonly reported TEAEs were nausea (12 patients, 54.5%); leukopenia, fatigue, and neutropenia (each in nine patients, 40.9%); dyspnea (seven patients, 31.8%); and anemia, hyperglycemia, hypertension, and hyponatremia (each in six patients, 27.3%). Reported bleeding events were epistaxis (three patients, 13.6%), vaginal hemorrhage (two patients, 9.1%), and hemoptysis (one patient, 4.5%); none of these events were grade 3.

Nine patients (40.9%) experienced a serious adverse event (SAE), seven of which were grade ≥ 3 (31.8%). Grade ≥ 3 SAEs included febrile neutropenia and dyspnea (each in two patients, 9.1%) and neutropenia, diarrhea, fatigue, and dehydration (each in one patient, 4.5%).

**Discussion**

This study investigated the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in patients with advanced malignant solid tumors resistant to standard therapy or for whom no standard therapy was available. In patients who completed both cycle 1 day 1 and cycle 2 day 1, dose-normalized $AUC_{(0-\infty)}$ and $C_{\text{max}}$ for docetaxel when administered with ramucirumab in cycle 2 were consistent with those when docetaxel was administered alone in cycle 1.

Because docetaxel is mainly metabolized by hepatic cytochrome P450 enzymes and monoclonal antibodies (mAbs) are eliminated...
through nonspecific, Fc receptor-mediated IgG clearance mechanisms and specific target-mediated drug disposition pathways, this finding was not unexpected [6,9]. The results of the present study are consistent with pharmacokinetic data from other clinical studies of docetaxel coadministered with mAbs showing the absence of an interaction between the agents [10-12].

The distribution into tissue of mAbs is known to be slow because of the molecular size of mAbs, and volumes of distribution are generally low [9]. Antibodies are protected from degradation by binding to protective receptors and therefore tend to have long elimination half-lives, up to 4 weeks [9]. The pharmacokinetics of ramucirumab were similar to that reported of other mAbs, with a long $t_{1/2}$ (geometric mean value 137 h), slow CL (geometric mean value 0.0184 L/h), and small $V_s$ following intravenous administration (geometric mean value 3.47 L).

Notably, greater patient variability was observed for docetaxel $C_{\text{max}}$ relative to AUC, which may contribute to the wider 90% CI for $C_{\text{max}}$ (90% CI: 0.84, 1.55) relative to AUC (90% CI: 0.84, 1.10). Nevertheless, the 90% CI of $C_{\text{max}}$ includes 1.00 and the 90% CI for AUC$_{0-\infty}$ is within the interval of 0.80-1.25, which supports the conclusion that coadministration of docetaxel with ramucirumab had no effect on the pharmacokinetics of docetaxel. Although not an objective of the study, results from a previous study that evaluated the pharmacokinetics of ramucirumab monotherapy [8] were compared to the pharmacokinetics of ramucirumab plus docetaxel in this study (Figure 4). The median values are similar, showing that coadministration of ramucirumab and docetaxel is unlikely to impact the pharmacokinetics of ramucirumab.

The combination of docetaxel (75 mg/m$^2$) once every 3 weeks with ramucirumab (10 mg/kg) was generally well tolerated. No deaths occurred during this study, and the most commonly reported TEAEs were nausea, fatigue, leucopenia, neutropenia, dyspnea, anemia, hyperglycemia, hypertension, and hyponatremia. The most commonly reported grade ≥ 3 TEAEs were leucopenia and neutropenia.

The docetaxel-related neutropenia events reported in this study are within the range cited in the literature [5,13,14]. In the REVEL trial, there was a greater incidence of any grade neutropenia in the ramucirumab plus docetaxel arm (345 patients, 55%) compared to the placebo plus docetaxel arm (284 patients, 45%) [5]; however, this study was not designed to detect such differences. No unexpected TEAEs or SAEs were observed with docetaxel in combination with ramucirumab or with docetaxel monotherapy in this study. The overall safety profile is consistent with what has been observed previously in ramucirumab clinical trials.

The results of this study supported the concomitant use of ramucirumab with docetaxel in the phase 3 REVEL trial for patients with advanced NSCLC [5]. This study demonstrated that ramucirumab plus docetaxel improves survival as second-line treatment compared to placebo plus docetaxel without significant increase in toxicity. The current clinical study confirms the absence of PK DDIs between docetaxel

Table 4: Mean pharmacokinetic parameters of ramucirumab administered as combination therapy with docetaxel.

| Parameter | Geometric Mean (CV%) Docetaxel + Ramucirumab (cycle 2) |
|-----------|------------------------------------------------------|
| $C_{\text{max}}$ | 303.6 | 28 |
| $C_{\text{max}}$ (μg/mL) | 0.365 | 34 |
| Dose-normalized $C_{\text{max}}$ | 0.7 | 137$^a$ |
| $t_{1/2}$ | (95.2-180) | |
| AUC$_{0-\infty}$ | 42400$^b$ | -32 |
| Dose-normalized AUC$_{0-\infty}$ | 54.4$^c$ | -29 |
| (μg x h/mL) | 0.0184$^d$ | -29 |
| CL | 3.47$^h$ | |
| $V_s$ | (L/h) | |
| $t_{1/2}$ | (L) | |
| $V_s$ | -43 | |

$^a$Geometric mean (range); $^b$n=11, because the AUC$_{0-\infty}$, was >30% or these parameters were not calculable because of missing data; $^c$AUC$_{0-\infty}$; Area under the plasma concentration-time curve from zero to infinity; $^d$AUC$_{0-\infty}$; Area under the plasma concentration-time curve from zero until the time of last measurable concentration to infinity; $^e$Maximum plasma drug concentration; $^f$Cl: Clearance; $^g$CV(%): Percentage coefficient of variation; $^h$n: number of subjects who had data for calculation of at least one pharmacokinetic parameter; $^i$t: Terminal half-life; $^j$V: Volume of distribution at steady state.

Figure 4: Ramucirumab dose-normalized $C_{\text{max}}$ and AUC values when administered alone and when administered following 75 mg/m$^2$ docetaxel administration. The lower boundary of the box indicates the 25th percentile, the line within the box marks the median, and the upper boundary of the box indicates the 75th percentile. The error bars above and below the box indicate the 90th and 10th percentiles, respectively. Black circles represent outlying points. AUC: Area under plasma concentration-time curve; $C_{\text{max}}$: Maximum plasma drug concentration; Doc: Docetaxel; n: Number of patients who had data for calculation of at least one pharmacokinetic parameter; Ram: Ramucirumab.
Citation: Stein MN, Chow LQM, Smith DC, Shepard DR, Wang D, et al. (2016) Phase II Study Evaluating the Effect of Concomitant Ramucirumab on the Pharmacokinetics of Docetaxel in Patients with Advanced Solid Tumors. Clin Pharmacol Biopharm 5: 161. doi: 10.4172/2167-065X.1000161

| Preferred term                  | Safety Population (N=22) n (%) | Any Grade | Grade ≥3 |
|---------------------------------|--------------------------------|-----------|----------|
| Nausea                          | 12 (54.5)                      | 0         |          |
| Leukopenia                       | 9 (40.9)                       | 7 (31.8)  |          |
| Fatigue                         | 9 (40.9)                       | 2 (9.1)   |          |
| Neutropenia                      | 9 (40.9)                       | 7 (31.8)  |          |
| Dyspnea                         | 7 (31.8)                       | 2 (9.1)   |          |
| Anaemia                          | 6 (27.3)                       | 1 (4.5)   |          |
| Hyperglycaemia                   | 6 (27.3)                       | 1 (4.5)   |          |
| Hypertension                     | 6 (27.3)                       | 1 (4.5)   |          |
| Hyponatraemia                    | 6 (27.3)                       | 0         |          |
| Alopecia                         | 5 (22.7)                       | 0         |          |
| Decreased appetite               | 5 (22.7)                       | 0         |          |
| Dysgeusia                        | 5 (22.7)                       | 0         |          |
| Constipation                     | 4 (18.2)                       | 0         |          |
| Diarrhoea                        | 4 (18.2)                       | 1 (4.5)   |          |
| Muscle spasms                   | 3 (13.6)                       | 1 (4.5)   |          |
| Epistaxis                        | 3 (13.6)                       | 0         |          |

Table 5: Treatment-emergent adverse events by preferred term.

and ramucirumab; therefore, no dosage adjustment is required due to DDI concerns when these agents are used concomitantly for the treatment of advanced cancers.

Acknowledgements

This study was funded by Eli Lilly and Company. The authors gratefully acknowledge Dr. Minori Koshiji for her contributions to this study. Eli Lilly and Company funded the medical writing support provided by Stacey E. Shehin, PhD, and Lucy Rutherford, the editorial support provided by Angela C. Lorio, ELS, and Jeanne Claypoole, all of whom are full-time employees of in Ventiv Health Clinical. This work was presented in part as an abstract at the American Society of Clinical Oncology Annual Meeting, 30 May 2014, Chicago, IL, and at the American Association of Pharmaceutical Scientists National Biotechnology Conference; San Diego, CA; 19 May 2014.

References

1. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
2. Zhu Z, Botlen P, Witte L (2002) Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2: 135-156.
3. Zhu Z, Witte L (1999) Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 17: 195-212.
4. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, et al. (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28: 780-787.
5. Garon EB, Ciuleanu TE, Arrieta O, Prabhak D, Syrigos K, et al. (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384: 665-673.
6. Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 45: 235-252.
7. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2012) Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.
8. Chow LQ, Smith DC, Tan AR, Denlinger CS, Wang D, et al. (2016) Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. Cancer Chemother Pharmacol 78: 433-441.
9. Keizer RJ, Hulstena AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49: 493-507.
10. Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T, et al. (2013) Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs 24: 1084-1092.
11. Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, et al. (2007) A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 97: 1336-1343.
12. Jatoi A, Jett JR, Sloan J, Novotny P, Ford J, et al. (2004) A pilot study on safety and pharmacokinetics of infliximab in the cancer anorexia/weight loss syndromes in non-small-cell lung cancer patients. Support Care Cancer 12: 859-863.
13. Baker SD, Li J, Ten Tije AJ, Figg WD, Graveland W, et al. (2005) Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77: 43-53.
14. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, et al. (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24: 4963-4970.